SULIMAN SHEHNAAZ (CIK 1713070) reported 14 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2026-09-24). Recent activity: Sell TXG (292 shares), Sell TXG (614 shares), Sell TXG (1,325 shares), Sell TXG (2,270 shares), Sell TXG (1,222 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-24 | 10x Genomics, Inc. (TXG) | Director | Sell | 292 | $22,833 |
| 2026-09-24 | 10x Genomics, Inc. (TXG) | Director | Sell | 614 | $48,820 |
| 2026-09-24 | 10x Genomics, Inc. (TXG) | Director | Sell | 1,325 | $107,082 |
| 2026-09-24 | 10x Genomics, Inc. (TXG) | Director | Sell | 2,270 | $185,391 |
| 2026-09-24 | 10x Genomics, Inc. (TXG) | Director | Sell | 1,222 | $100,542 |
| 2026-08-26 | 10x Genomics, Inc. (TXG) | Director | Sell | 561 | $35,189 |
| 2026-08-26 | 10x Genomics, Inc. (TXG) | Director | Sell | 1,646 | $105,289 |
| 2026-06-18 | 10x Genomics, Inc. (TXG) | Director | Sell | 5,359 | $174,650 |
| 2026-06-18 | 10x Genomics, Inc. (TXG) | Director | Sell | 364 | $12,110 |
| 2026-06-08 | 10x Genomics, Inc. (TXG) | Director | Buy | 8,829 | $0 |
| 2026-05-18 | Ultragenyx Pharmaceutical Inc. (RARE) | Director | Buy | 7,751 | $0 |
| 2026-05-18 | Ultragenyx Pharmaceutical Inc. (RARE) | Director | Sell | 5,740 | $144,189 |
| 2025-06-05 | 10x Genomics, Inc. (TXG) | Director | Buy | 15,357 | $0 |
| 2025-05-19 | Ultragenyx Pharmaceutical Inc. (RARE) | Director | Buy | 5,740 | $0 |
来源：SEC Form 4 申报文件 · 截至 2026-09-24